Olmibite Beta 25 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 25 mg, formulated as an extended-release tablet. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The combination of these agents provides complementary mechanisms to effectively manage hypertension, reducing the risk of cardiovascular morbidity and mortality. Olmibite Beta 25 Tablet ER is indicated for the treatment of essential hypertension in patients who require dual therapy for optimal blood pressure control. The extended-release formulation ensures sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. Caution is advised in patients with bradycardia, heart block, severe hepatic impairment, or asthma. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This medication should be used under medical supervision with consideration of individual patient risk factors.